Sorrento Announces Phase 2 Abivertinib Clinical Studies Have Completed Patient Enrollment in USA and Brazil with Top-Line Clinical Data Expected End of 3Q21
June 22, 2021 09:00 ET
|
Sorrento Therapeutics, Inc.
Phase 2 US clinical trial of Abivertinib randomized last patient (#96) on 4/07/2021.Phase 2 Brazilian clinical trial of Abivertinib randomized last patient (#400) on 06/20/2021.Studies are...
Sorrento Completes Acquisition of ACEA Therapeutics, Creating a Major Oncology Franchise
June 02, 2021 09:00 ET
|
Sorrento Therapeutics, Inc.
AMONG MULTIPLE CLINICAL- AND PRECLINICAL-STAGE NCE (NEW CHEMICAL ENTITY) COMPOUNDS ACQUIRED, ABIVERTINIB IS AN ANCHORING LATE-STAGE DRUG PRODUCT WITH POSITIVE CLINICAL TRIAL RESULTS IN BOTH NON-SMALL...
Brazilian Health Regulatory Agency (ANVISA) Authorizes Sorrento Therapeutics’ Large Phase 2 Clinical Trial of Abivertinib in Mild, Moderate and Severe COVID-19 Patients
October 14, 2020 11:57 ET
|
Sorrento Therapeutics, Inc.
Phase 2 clinical trials of Abivertinib now cleared to proceed in both Brazil and the U.S.Studies are complementary and address both dose duration and disease stageRapid enrollment expected for both...
Sorrento to Host a R&D Day to Showcase COVID-19 Product Pipeline
October 04, 2020 18:39 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Oct. 04, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced it will host a R&D Day conference call and simultaneous webcast on October...